viralic
Forumer storico
Slide 18 has comments on Vyzulta:
“VYZULTA® TRx weekly scripts grew >50% in 4Q18 vs. 3Q18
• Patients who start on VYZULTA® are 34% more likely to stay on it than other branded agents5
• ~30% of prescriptions are newly diagnosed glaucoma patients; of the remaining 70% prescriptions, ~50% are switches from generic latanoprost and ~50% are switches from other branded agents5
• Coverage: ~80% Commercial Coverage (including ESI and CVS) and 30% Medicare Part D Coverage; however, more than half of Part D prescriptions are being reimbursed8
• Approved in Canada as of Jan. 2019”
“VYZULTA® TRx weekly scripts grew >50% in 4Q18 vs. 3Q18
• Patients who start on VYZULTA® are 34% more likely to stay on it than other branded agents5
• ~30% of prescriptions are newly diagnosed glaucoma patients; of the remaining 70% prescriptions, ~50% are switches from generic latanoprost and ~50% are switches from other branded agents5
• Coverage: ~80% Commercial Coverage (including ESI and CVS) and 30% Medicare Part D Coverage; however, more than half of Part D prescriptions are being reimbursed8
• Approved in Canada as of Jan. 2019”